Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/11/2025 | $76.00 | Overweight | Cantor Fitzgerald |
| 6/12/2025 | $62.00 | Buy | BTIG Research |
| 6/10/2025 | Outperform | William Blair | |
| 2/6/2025 | $57.00 | Buy | H.C. Wainwright |
| 12/4/2024 | $73.00 → $69.00 | Buy | B. Riley Securities |
| 4/11/2024 | $24.00 | Buy | Craig Hallum |
| 9/8/2022 | $17.00 | Buy | B. Riley Securities |
| 10/14/2021 | $16.00 | Buy | B. Riley Securities |
8-K - HARROW, INC. (0001360214) (Filer)
10-Q - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)
NASHVILLE, Tenn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following two investor conferences in December: BTIG 5th Annual Ophthalmology Day (Virtual)Format: Fireside chatDate/Time: Monday, December 1, 2025, at 8:30 AM EST Piper Sandler 37th Annual Healthcare Conference (New York, NY)Format: Fireside chatDate/Time: Tuesday, December 2, 2025, at 3:00 PM EST The fireside chat at Piper Sandler will be webcast live and can be found on the Event's page on the Company's website. A replay will be available for approximately 90 days following the
NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acquisition of Melt Pharmaceuticals, Inc. (Melt), a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office settings. Melt's product candidates, MELT-210, MELT-300, and MELT-400, are based on the proprietary Zydis® ODT (oral dissolving tablet) drug delivery platform. The closing of the Melt acquisition marks a strategic expansion of Harrow's portfolio and reinforces its commitment to delivering inn
Third-Quarter 2025 and Recent Selected Highlights: Total revenues of $71.6 million, a 45% increase over $49.3 million recorded in the prior-year periodGAAP net income of $1.0 millionAdjusted EBITDA of $22.7 millionCash and cash equivalents of $74.3 million as of September 30, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the third quarter ended September 30, 2025. The Company also posted its third quarter Letter to Stockholders and corporate presentation to the "Inve
3 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
3 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
Cantor Fitzgerald initiated coverage of Harrow with a rating of Overweight and set a new price target of $76.00
BTIG Research initiated coverage of Harrow with a rating of Buy and set a new price target of $62.00
William Blair initiated coverage of Harrow with a rating of Outperform
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Mike Biega has joined Harrow as Vice President of Investor Relations and Communications, succeeding Jamie Webb, Director of Communications and Investor Relations, who recently announced her retirement. Jamie will remain in her role into August to support a smooth and effective transition. "We are excited to welcome Mike to the Harrow Family. His wealth of experience in investor relations and strategic communications will be a tremendous asset as we pursue our objective of becoming the leading U.S. ophthalmic pharmaceutical company," said Mark L. Baum, Chief Executive Officer of Harrow. "I a
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including groundbreaking work in anterior and posterior segment ophthalmic indications. Dr. Shojaei most recently served as CSO and Executive Vice President of Clinical Development at AsclepiX Therapeutics, where he spearheaded the development of innovative therapies for neovascular retinal disorders. P
Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow's rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow's commitment to enhancing its leadership structure to support the Company's continued growth. John Saharek, Harrow's Chief Commercial Officer and Chief Executive Officer of ImprimisRx, will continue to oversee Harrow's commercial business, focusing on the day-to-day management of Harrow's market‑leading compounded division. DiPasquale
SC 13G/A - HARROW, INC. (0001360214) (Subject)
SC 13G/A - HARROW, INC. (0001360214) (Subject)
SC 13G/A - HARROW, INC. (0001360214) (Subject)
Third-Quarter 2025 and Recent Selected Highlights: Total revenues of $71.6 million, a 45% increase over $49.3 million recorded in the prior-year periodGAAP net income of $1.0 millionAdjusted EBITDA of $22.7 millionCash and cash equivalents of $74.3 million as of September 30, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the third quarter ended September 30, 2025. The Company also posted its third quarter Letter to Stockholders and corporate presentation to the "Inve
NASHVILLE, Tenn., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the third quarter ended September 30, 2025, on Monday, November 10, 2025, after the market close. The Company will also post its third quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, November 11, 2025, to discuss the results and provide a business update. Conference Call InformationParticipants can access the live webcast of Harrow's presentation on t
Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year periodGAAP net income of $5.0 millionAdjusted EBITDA of $17.0 millionCash and cash equivalents of $53.0 million as of June 30, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the second quarter ended June 30, 2025. The Company also posted its second quarter Letter to Stockholders and corporate presentation to the "Investors" s